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Abstract
Background—The United States Cancer Statistics (USCS) are the official federal cancer 
statistics and contain the most complete and accurate data. Yet, the data are typically older than 24 
months by the time they are published. The National Program of Cancer Registries (NPCR) 
contributes 96% of the data in USCS and has been collecting preliminary data since 2000, though 
the quality of these data has not been published. The objective of this analysis is to determine how 
accurately preliminary cancer data submitted by NPCR grantees predict cancer rates eventually 
published in USCS.
Methods—Cancer data were obtained for diagnosis year 2012 among all cancer sites combined 
and a subset of 20 cancer sites that were used to test completeness of case ascertainment. Age-
adjusted incidence rates (IR), rate ratios (RR), and 95% CIs were calculated for data submitted in 
November 2013 (NPCR preliminary, or 12-month data)—794,413 cases—and compared to USCS, 
which uses data submitted in November 2014 (24-month data)—1,529,078 cases.
Results—For all cancer sites and all races combined, the incidence rates for the NPCR 
preliminary data were slightly lower than the rate obtained through USCS (401.3 vs 440.3), but 
showed comparability (RR = 0.91). Regardless of race, 75% of the cancer sites had rate ratios of at 
least 0.90. For hospitals or clinics, the site-specific RRs were high, but RRs were more variable for 
other non-hospital centers and were lower for cases obtained from death certificates and autopsies. 
More than half (56%) of the US population and 87% of cancer cases diagnosed in 2012 were 
represented by the states included in the preliminary data set.
Discussion—This is the first known study examining cancer incidence rates calculated using 
earlier cancer surveillance data than is traditionally used. The strengths of this analysis include the 
representativeness of the sample and comparability with the USCS data. Our results also show 
that, compared to other sources, early reporting from hospitals most accurately estimates cancer 
rates in USCS.
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Conclusion—Preliminary cancer data may accurately estimate the official federal cancer 
incidence rates for the 2012 diagnosis year and supports the possibility of using these data as an 
early preview of cancer incidence rates.
Keywords
cancer surveillance; National Program of Cancer Registries; preliminary data
Introduction
The National Program of Cancer Registries (NPCR) administered by the Centers for Disease 
Control and Prevention (CDC) supports central cancer registries (CCRs) in 45 states, the 
District of Columbia, Puerto Rico, and the United States Pacific Island Jurisdictions to 
routinely collect data on patient demographics, primary tumor site, tumor morphology, stage 
at diagnosis, first course of treatment, and outcomes. The National Cancer Institute (NCI)’s 
Surveillance, Epidemiology, and End Results (SEER) Program supports CCRs in the 
remaining 5 states and various substate regions, and provides additional support to select 
NPCR-supported CCRs. Together, NPCR and SEER cover the entire US population for 
cancer surveillance. NPCR and SEER combined cancer data are the source of the official 
federal statistics on cancer incidence, the United States Cancer Statistics (USCS).1
Each year, NPCR and SEER data on newly diagnosed cases, as well as updated data from 
previous diagnosis years, are submitted by CCRs to NPCR, SEER, or both. The entire 
longitudinal data set is resubmitted each year to allow for the capture of additional cases that 
were reported or to append updated information (eg, treatment or vital status information) 
received after the last data submission. CCRs are allowed a follow-up interval of 22 to 23 
months after the close of the diagnosis year for submission to ensure completeness of case 
ascertainment and high-quality data. These data are used to publish USCS and are often 
referred to by CCRs as the 24-month data. Hereafter, we refer to the 24-month data from 
both NPCR and SEER as USCS data.
NPCR CCRs are also required to submit preliminary data for the diagnosis year that closed 
approximately 12 months before the date of submission (hereinafter referred to as 
preliminary data). However, to date, preliminary cancer data have not been published since 
completeness of case ascertainment and data quality have not been formally evaluated. 
Completeness of case ascertainment for USCS is currently calculated using methods 
established by North American Association of Central Cancer Registries (NAACCR).2 At 
the time this analysis was conducted, NPCR data were only included in the USCS data set 
when the submitting registry’s completeness of case ascertainment met 90% of the expected 
cases with a margin of error of ±5% along with other NPCR data standards: age, sex, and 
county (<3% missing), race (<5% missing), and death-certificate only (DCO) cases <5%.1
Other data systems, such as FoodNet and those from the National Center for Health 
Statistics, have published results using preliminary surveillance data.3,4 One study from NCI 
discusses their cancer reporting-adjustment model that is used to estimate current cancer 
incidence rates and trends.5 However, NCI’s routine delay-adjusted rates produce estimated 
projections rather than scrutinizing observed data submitted at an earlier point in time.
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The objective of this analysis is to compare the preliminary cancer data submitted by NPCR 
grantees to the official federal statistics, USCS.
Methods
Data Source
NPCR cancer data were obtained from CDC for diagnosis year 2012. We compared data 
submitted in November 2013 (NPCR preliminary data)—794,413 cases—to those 
resubmitted in November 2014 and appended to data obtained through a similar submission 
schedule from NCI’s 5 SEER-only state CCRs for inclusion in USCS—1,529,078 cases. The 
NPCR preliminary data set was restricted to states that met NPCR’s completeness of case 
ascertainment and data quality standards for inclusion in USCS, with the exception that we 
modified the completeness threshold to 80% from 90%, which is what is expected at 24 
months. Preliminary data from the 5 SEER-only state CCRs, comprising about 4% of cases 
diagnosed in the United States each year, were not available for this analysis. The NPCR-
funded states that met the preliminary data quality criteria included Alabama, California, 
Colorado, Delaware, Georgia, Florida, Idaho, Illinois, Kansas, Kentucky, Louisiana, Maine, 
Missouri, Mississippi, Montana, North Carolina, Nebraska, New Hampshire, New Jersey, 
New York, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Vermont, 
Wisconsin, West Virginia, and Wyoming. These states represent 56% of the US population 
for 2012. As expected, most CCRs (51, including the District of Columbia and Puerto Rico) 
met 24-month data quality criteria for this same diagnosis year and included both NPCR and 
SEER-only registry data, representing 95% of the US population for 2012.1
For this analysis, we limited cancer sites to all sites combined plus 20 individual sites that 
were used to test completeness of case ascertainment: oral cavity and pharynx (oral); 
esophagus; stomach; colon and rectum (colorectal); liver and intrahepatic bile duct (liver); 
pancreas; lung and bronchus (lung); melanomas of the skin (melanomas); female breast; 
cervix uteri (cervical); corpus and uterus, NOS (uterine); ovary; prostate; urinary bladder 
(bladder); kidney and renal pelvis (kidney); brain and other nervous system (brain); Hodgkin 
lymphoma; non-Hodgkin lymphoma; myeloma; and leukemias. The preliminary data set 
covers more than half (56%) of the US population and 87% of cancer cases diagnosed in 
2012. The comparison data set, USCS, covers 95% of the US population and 99% of the 
cancer cases diagnosed in 2012.
Statistical Analysis
SEER*Stat v. 8.3.2 was used to calculate age-adjusted incidence rates (IRs), rate ratios 
(RRs), and 95% CIs for both NPCR preliminary and USCS data by race (white, black, 
Asian/Pacific Islander [API]), cancer site, and reporting source.6 We determined that the 
threshold of an RR between 0.90 and 1.10 indicated comparability between the preliminary 
and USCS data. This range was chosen for consistency because 90% completeness is the 
standard used for a state’s data to be included in USCS. American Indian/Alaska Natives 
(AI/ANs) were excluded from the analysis by race because of small case counts. Type of 
reporting source, as reported to the CCRs, included hospital or clinic; other nonhospital 
center (radiation treatment or medical oncology center, hospital or private laboratory only, 
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physician’s office/private medical practitioner, or other hospital outpatient unit or surgery 
center); DCO; and autopsy only.
Results
Table 1 shows the IRs, RRs, and 95% CIs for the preliminary data compared to USCS by 
cancer site and race. For all sites, all races combined, the IR for the NPCR preliminary data 
was slightly lower than the rate obtained through USCS (401.3 vs 440.3), but showed 
comparability (RR = 0.91). Regardless of race, 75% (15/20) of cancer sites had RRs of at 
least 0.90. Those below this threshold were liver (0.83), pancreas (0.88), prostate (0.89), 
myeloma (0.86), and leukemias (0.85). The site-specific RRs among whites followed a 
similar pattern as seen in all races combined; however, more sites fell below a RR of 0.90 for 
both blacks and APIs.
Table 2 illustrates the IRs, RRs, and 95% CIs for the preliminary data compared to USCS by 
cancer site and type of reporting source. For hospitals or clinics, the site-specific RRs were 
relatively high, ranging from 0.88 to 0.96 for all sites except melanomas (RR = 0.64) and 
brain (RR = 0.35). The site-specific RRs for nonhospital centers were more variable, ranging 
from as high as 1.17 for Hodgkin lymphoma to as low as 0.21 for brain cancers, with 60% of 
the sites having a RR above 0.90. IRs obtained from DCO and autopsy only cases were 
substantially lower in the preliminary data as compared to USCS data.
Table 3 shows the percent of USCS case counts represented by preliminary data. Overall, the 
preliminary data represent 52% of the official federal case counts (Table 3), corresponding to 
a 56% total US population coverage from the registries included in the NPCR preliminary 
data set (data not shown). There is variation by cancer site, with the highest representation 
for uterine cancer (56%) and lowest for liver cancer (47%) and leukemias (48%).
Discussion
This is the first known analysis examining cancer incidence rates calculated using cancer 
surveillance data that are submitted earlier than is traditionally used for USCS. For those 
states that met NPCR’s standards for 80% completeness and other quality measures, the 
preliminary data may produce cancer incidence rates comparable to those obtained in USCS 
for diagnosis year 2012 (within 10% variation from USCS). Among all races combined as 
well as for whites, the majority of the cancer sites examined had RRs above the threshold of 
comparability. Furthermore, 52% of RRs for cases reported by hospitals and 48% of RRs by 
nonhospital centers were within the threshold of comparability.
However, despite the comparability of the preliminary data, some parameters need to be 
considered when using the preliminary data. Special focus should be paid to liver, pancreas, 
myeloma, and leukemias because the rates are significantly lower than expected at 24 
months. Liver and pancreas cancers are highly fatal and often found as DCOs, which are 
usually delayed in reporting. Additionally, myeloma and leukemias are rare, so there is a less 
robust comparison among low case counts.
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This examination of preliminary data reveals cautionary examples for comparison of cancer 
rates by race. Cancer rates for all sites in the preliminary data are higher among whites than 
blacks; however, in USCS, the opposite is the case, where blacks have higher rates than 
whites. Furthermore, case counts among AI/ANs were too low in the preliminary data set to 
be used for racial comparisons in this analysis. Rate ratios among blacks and APIs were also 
more likely to fall below 0.9 than among whites, who showed similar patterns to all races 
combined. These data shed light on the need to improve timely data capture of nonwhite 
populations at 12 months.
Our results show that, compared to other sources, early reporting from hospitals most 
accurately estimates cancer incidence rates in USCS. Regardless of reporting source, the 2 
sites that exhibited rate ratios far below 0.90, melanomas and brain cancer, are typically 
diagnosed and treated outside of the hospital setting, which leads to reporting delays due to 
obtaining additional information on laboratory reports. For example, primary treatment for 
uterine cancer is surgery and the RR by hospital source is 95%, indicating timely reporting 
from those sources. By contrast, while the USCS data quality standards allow for DCOs of 
less than 5%, 3 sites were the closest to that cutoff in the USCS data: liver at 5%, pancreas at 
4%, and brain at 4%. DCOs are not typically added by the CCRs until all other sources have 
reported. While both lymphoma and leukemias are often diagnosed and treated in the 
outpatient setting, the RRs of preliminary data compared to USCS are similar between 
lymphoma and leukemias by reporting source; however, without considering reporting 
source, the RR for leukemias is lower compared to lymphoma (0.85 vs 0.90). This may 
indicate that overall capture of lymphoma cases at 12 months is better compared to leukemia 
cases and may be due to lymphoma more likely being diagnosed pathologically, which is a 
primary source of early reporting for the CCRs. Furthermore, there are 2 cancer sites with 
rate ratios above 1.10 reported by nonhospital centers: female breast (1.15) and non-
Hodgkin lymphoma (1.17). These sites had higher rates in the preliminary data compared to 
the USCS data, which may, in part, be related to more cases received through electronic 
reporting. Overall, reporting of cases diagnosed and treated in the outpatient setting has been 
lacking over the past few years, but has shown improvement recently based on other 
unpublished analyses. 7 Although the absolute difference in rates between the preliminary 
data and USCS was greater than 10 among all sites combined and prostate cancer, the RR 
for those sites is approximately 0.90, indicating comparability in the data.
The strengths of this analysis are the representativeness of the sample where 56% of the US 
population and 87% of cancer cases diagnosed in 2012 were represented by the states 
included in the preliminary data set. The comparison data set, USCS, covers 95% of the US 
population and 99% of the cancer cases diagnosed in 2012.
Some limitations of this study include narrow focus to 1 year of data for consideration and 
no consideration of ethnicity due to low case counts resulting in IRs and RRs that were 
considered unreliable. We have noticed, based on previous, unpublished analyses, that the 
number of cases reported as preliminary data varies slightly by year due to competing 
resources at the CCR and external factors (such as coding and staging changes). Future 
research is warranted into variations between diagnosis years. Furthermore, the preliminary 
data that we examined for this analysis did not include the 5 state CCRs that are funded 
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exclusively by NCI’s SEER program, which could contribute to lower comparability as 
inclusion may increase the IRs and RRs, though state CCRs funded solely by NCI represent 
only 4% of all cancer cases and the population in the United States. However, further 
evaluation whether a combined NPCR+SEER data set for preliminary data would be more 
comparable to the USCS data may be warranted given the availability of these data at NCI. 
Although the NCI data represent a small percentage of cases, the distribution of cancer sites 
in that data set may have an impact on the cancer sites evaluated in this study. Lastly, we did 
not attempt any mathematical modeling to determine the relationship between preliminary 
and USCS data. Future work in this area could help inform the ongoing development of 
delay-adjustment models or additional projection methodologies that could be applied to 
preliminary data in addition to methodologies currently applied to the 24-month data.
Similar to other natality and mortality surveillance systems, our analyses showed that 
publication of preliminary cancer incidence rates may be possible. Ultimately, utilization of 
preliminary data may improve timeliness of cancer data reporting while taking into 
consideration registry processes such as reporting sources having 6 months to report a case 
and the registry doing quality checks and linkages before submission to NPCR. Based upon 
the dynamic nature of cancer registration and that the preliminary incidence rates are lower 
than the official incidence rates, rates and counts based upon the most complete data as 
published in USCS need to remain the data source for program planning and other related 
activities. CDC will work with our USCS collaborating partners to determine whether 
preliminary rates from all partners can be published through USCS in the future. In 
conclusion, the preliminary data received by CCRs at NPCR appear to be a relatively 
accurate source of early cancer incidence rates.
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Table 3
Percent of USCS Case Count Represented by Preliminary Data for Diagnosis Year 2012 by Site
Site Preliminary Case Count USCS Case Count Percent
All cancer sites 794,413 1,529,078 52
Oral cavity and pharynx 20,849 39,879 52
Esophagus 8,243 15,993 52
Stomach 12,372 22,623 55
Colon and rectum 71,681 134,784 53
Liver and intrahepatic bile duct 13,277 28,012 47
Pancreas 21,581 43,213 50
Lung and bronchus 108,179 210,828 51
Melanomas of the skin 35,574 67,753 53
Female breast 121,531 224,147 54
Cervix 6,598 12,042 55
Corpus and uterus, NOS 26,617 47,570 56
Ovary 10,867 20,785 52
Prostate 90,791 177,489 51
Urinary bladder 36,219 69,974 52
Kidney and renal pelvis 28,449 55,231 52
Brain and other nervous system 11,044 21,490 51
Hodgkin lymphoma 4,380 8,273 53
Non-Hodgkin lymphoma 32,839 63,419 52
Myeloma 10,835 21,829 50
Leukemias 21,396 44,396 48
NOS, not otherwise specified; USCS, United States Cancer Statistics.
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